Sangstat Medical Corporation

Drugabuse Sciences, Inc.

Other

The University of North Carolina at Chapel Hill

Conjuchem, Inc.

Redcell Canada, Inc.

Redcell, Inc.

Sangstate Medical Corporation

Philippe J Pouletty

Ralph E Levy

Moo J Cho

Roland Buelow

Chin-Hai Chang

Herve Galons

Alexander R Lussow

Christine Pouletty

Jean-Michel Scherrmann

Peter Chun

Beth Atwood

Laurence R Nicholson

Cliff Tyner

Thomas Ingalz

David Rammler

Robert A Britts

Chin H Chang

Debra L McEnroe

Ralph F Levy

Teresa Kendreck

David Rommler

The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.

Cocaethylene immunogens and antibodies

Improved oral cyclosporin formulations which have high bioavailability and are capable of admiration in hard capsules are provided. In the subject formations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. The subject formalations may further comprise at least one cosolvent, where cosolvents of interest include fatty acids and diols. The subject formulations find use in immuno-suppressive therapy.

Oral cyclosphorin formulations

A liquid medication dispenser apparatus which provides for user-friendly medication measurement and compliance. The apparatus measures and dispenses liquid medication doses and records the time and dose sizes for up to one year. The recorded information can then be downloaded to a personal computer for evaluation of patient compliance. A disposable, motor driven pump is used to provide a very wide range of medication dispensation volumes, while maintaining full accuracy and reducing the risks of patient errors as might occur with a manual dispense system.

Liquid medication dispenser apparatus

First and second compounds are provided, where the first compound is administered to a mammalian host into blood for covalent bonding to blood components, where the components have an extended lifetime in the blood stream. The first compound comprises an active functionality and an agent of interest or a first binding entity. A second compound may be subsequently administered to the patient, which comprises a second binding entity, complementary to the first binding entity and an agent of interest. By virtue of binding to long-lived blood components, the half-life of the agent of interest is greatly extended in vivo.

Cellular and serum protein anchors and conjugates

Improved oral cyclosporin formulations which have high bioavailability and are capable of administration in both liquid and hard capsule form are provided. In the subject formulations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. The subject formulations may further comprise at least one cosolvent, where cosolvents of interest include fatty acids and diols. The subject formulations find use in immuno-suppressive therapy.

Oral cyclosporin formulations

Compounds and libraries are labeled with a galactosyl epitope and then screened in accordance with an assay involving cells having a characteristic of interest. Conveniently, the screening may embody target cells, where the compounds are brought in contact with the cells. Each of the compounds carries with it the information of its identity or method of synthesis. After washing away non-specifically bound compounds, blood may be applied to the cells, whereby antibody binding to the galactosyl epitope initiates the complement cascade. Plaques are identified and the compound associated with the plaque identified. The formation of the plaque demonstrates that the compound has specific affinity for the target cell, binding of the compound to the cell does not interfere with binding of the antibody, and that the complex is capable of cytotoxic activity by means of the complement cascade.

Anti .alpha.-gal screening technique

Novel bifunctional reagents useful in reducing the biological effect of an undesirable blood-borne agent are provided. The reagents comprise conjugates of a first binding member specific for a blood-borne agent having a detrimental biological activity in a mammalina host, such as a growth factor, coagulation factor, enzyme, toxin, drug of abuse, microbe, autoreactive immune cell, infected or tumorous cell, joined to an second binding member specific for an anchor, where the anchor is a long-lived blood component, including cells, such as a erythrocyte, platelet or endothelial cell and serum proteins, such as albumin, ferritin, or steroid binding proteins. These conjugates find therapeutic use by coupling the agent and the blood component and thereby reducing the biological activity or effective concentration of free agent, modulating the volume of distribution of the agent, targeting the agent to sites of enhanced immune response, or facilitating agent clearance from the bloodstream.

Cellular and serum protein anchors for modulating pharmacokinetics

Improved oral cyclosporin formulations which have high bioavailability and are capable of administration in hard capsules, are provided. In the subject formulations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant and an ester of an alcohol and a fatty acid having a hydrocarbon chain of from 14 to 18 carbon atoms. The subject formulations find use in immunosuppressive therapy.

Oral cyclopsporin formulations

Improved oral cyclosporin formulations which have high bioavailability and are capable of administration in hard capsules are provided. In the subject formulations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. The subject formulations may further comprise at least one cosolvent, where cosolvents of interest include fatty acids and diols. The subject formulations find use in immuno-suppressive therapy.

Compounds and libraries are labeled with a galactosyl epitope amd then screened in accordance with an assay involving cells having a characteristic of interest. Conveniently, the screening may embody target cells, where the compounds are brought in contact with the cells. Each of the compounds carries with it the information of its identity or method of synthesis. After washing away non-specifically bound compounds, blood may be applied to the cells, whereby antibody binding to the galactosyl epitope initiates the complement cascade. Plaques are identified and the compound associated with the plaque identified. The formation of the plaque demonstates that the compound has specific affinity for the target cell, binding of the compound to the cell does not interfere with binding of the antibody, and that the complex is capable of cytotoxic activity by means of the complement cascade.

Super-globuling for in vivo extended lifetimes

Methods and compositions are provided for the determination of cross-reactive alleles, where there is no antibody which will specifically distinguish between the two alleles. Particularly, the method employs an antibody which binds to the two alleles bound to a surface, an antibody specific for one of the alleles, a labeled conjugate which binds to a consensus sequence present in both alleles and positive and negative controls. By having an enhanced value where the interfering allele is present as compared to a value for the target allele, one can distinguish between the various alternatives involving the presence or absence of one or both alleles.

Growing community of inventors

Atherton, CA, United States of America

Philippe J Pouletty